Citalopram-induced bradycardia and presyncope

被引:17
作者
Isbister, GK
Prior, FH
Foy, A
机构
[1] Newcastle Mater Hosp, Hunter Drug Informat Serv, Newcastle, NSW, Australia
[2] Newcastle Mater Hosp, Dept Med, Newcastle, NSW, Australia
关键词
bradycardia; citalopram;
D O I
10.1345/aph.1A136
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To report a case of symptomatic bradycardia and hypotension that resulted from the therapeutic use of citalopram and to review any previous reports in the literature, from the manufacturer, and the Australian Drug Reaction Advisory Committee (ADRAC). CASE SUMMARY: A 60-year-old white woman who had been taking citalopram 20 mg/d for two weeks presented to the hospital with a heart rate of 39 beats/min, mild hypotension (systolic BP 105 mmHg), and a normal electrocardiogram (QTc <440 msec), following a presyncopal episode. The patient was admitted for cardiac monitoring, and citalopram was discontinued. The bradycardia and hypotension resolved in the 48-hour period following cessation of citalopram. No other medical or pharmacologic cause was found for the adverse drug reaction. DISCUSSION: Bradycardia has been reported rarely with citalopram in therapeutic doses, but this is the first detailed case with a dose of only 20 mg. The manufacturer reports bradycardia as an infrequent adverse effect (0.1-1%) of citalopram. There have been no reports to ADRAC or to the manufacturer in postmarketing surveillance. There is a case report of asymptomatic bradycardia in a patient whose dose was increased to 40 mg. In the case reported here, there was no QTc prolongation consistent with previous reports. The sinus bradycardia reported more often with therapeutic doses would appear to be distinct to QT abnormalities seen with citalopram overdose. CONCLUSIONS: Citalopram should be used with care in the elderly and in persons with a history of heart disease. Heart rate and blood pressure should be monitored in the first week of therapy and when doses are modified.
引用
收藏
页码:1552 / 1555
页数:4
相关论文
共 22 条
[1]  
[Anonymous], CESKA SLOVENSKA PSYC
[2]  
Barbey JT, 1998, J CLIN PSYCHIAT, V59, P42
[3]   CITALOPRAM IN DEPRESSION - METAANALYSIS OF INTENDED AND UNINTENDED EFFECTS [J].
BECH, P ;
CIALDELLA, P .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1992, 6 :45-54
[4]   CITALOPRAM - A HIGHLY SELECTIVE 5-HT UPTAKE INHIBITOR IN THE TREATMENT OF DEPRESSED-PATIENTS - AN OPEN CLINICAL-TRIAL WITH STEADY-STATE CONTROL [J].
DUFOUR, H ;
BOUCHACOURT, M ;
THERMOZ, P ;
VIALA, A ;
ROP, PP ;
GOUEZO, F ;
DURAND, A ;
PETERSEN, HEH .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1987, 2 (03) :225-237
[5]   A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice [J].
Ekselius, L ;
von Knorring, L ;
Eberhard, G .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1997, 12 (06) :323-331
[6]   Bradycardia during citalopram treatment: A case report [J].
Favre, MP ;
Sztajzel, J ;
Bertschy, G .
PHARMACOLOGICAL RESEARCH, 1999, 39 (02) :149-150
[8]  
*FOR PHARM US, PROD INF CEL TM CIT
[9]  
KENNEDY DL, 2000, PHARMACOEPIDEM DR S, P151
[10]   Selective serotonin reuptake inhibitor-induced serotonin syndrome: Review [J].
Lane, R ;
Baldwin, D .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1997, 17 (03) :208-221